Genelux (NASDAQ:GNLX) Issues Earnings Results

Genelux (NASDAQ:GNLX – Get Free Report) issued its quarterly earnings results on Monday. The company reported ($0.23) earnings per share for the quarter, missing the consensus estimate of ($0.19) by ($0.04), Zacks reports.

Genelux Stock Performance

Shares of NASDAQ:GNLX traded up $0.06 during midday trading on Monday, reaching $1.92. 277,007 shares of the company’s stock traded hands, compared to its average volume of 256,074. The company has a fifty day simple moving average of $2.31 and a two-hundred day simple moving average of $2.65. Genelux has a 1 year low of $1.77 and a 1 year high of $5.89. The company has a market cap of $86.87 million, a P/E ratio of -2.23 and a beta of 0.68.

Analyst Ratings Changes

Several equities analysts recently weighed in on GNLX shares. Wall Street Zen upgraded shares of Genelux from a “strong sell” rating to a “sell” rating in a report on Tuesday, October 20th. Weiss Ratings reissued a “sell (e+)” rating on shares of Genelux in a research report on Thursday, October 15th. Lucid Cap Mkts upgraded shares of Genelux to a “strong-buy” rating in a research note on Wednesday, September 16th. Finally, Benchmark reaffirmed a “speculative buy” rating on shares of Genelux in a report on Tuesday, August 18th. One equities research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $20.00.

Get Our Latest Research Report on GNLX

Insider Buying and Selling at Genelux

In related news, CEO Thomas Zindrick sold 34,463 shares of the business’s stock in a transaction on Monday, August 31st. The shares were sold at an average price of $2.67, for a total value of $92,016.21. Following the completion of the sale, the chief executive officer owned 1,226,427 shares of the company’s stock, valued at approximately $3,274,560.09. The trade was a 2.73% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Yong Yu sold 9,683 shares of the company’s stock in a transaction on Monday, August 31st. The stock was sold at an average price of $2.75, for a total transaction of $26,628.25. Following the transaction, the insider owned 258,688 shares of the company’s stock, valued at $711,392. This represents a 3.61% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last three months, insiders sold 47,903 shares of company stock valued at $126,320. 7.50% of the stock is owned by insiders.

Genelux Company Profile

(Get Free Report)

Genelux Corporation is a clinical-stage biotechnology company focused on developing oncolytic immunotherapies for cancer. Its research centers on engineered viruses designed to target and destroy cancer cells while stimulating an immune response against tumors. The company’s lead candidate is olvimulogene nanivacirepvec, also known as Olvi-Vec, an engineered vaccinia virus being studied in clinical trials for ovarian cancer and other solid tumors. Genelux is also advancing additional candidates based on its oncolytic virus platform.

Read More

Earnings History for Genelux (NASDAQ:GNLX)

Receive News & Ratings for Genelux Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genelux and related companies with MarketBeat.com's FREE daily email newsletter.